User:Mr. Ibrahem/Ruxolitinib
 | |
| Clinical data | |
|---|---|
| Pronunciation | Jakafi /ˈdʒækəfaɪ/ JAK-ə-fye |
| Trade names | Jakafi, Jakavi |
| Other names | INCB018424, INC424 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a612006 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Kinase inhibitor[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 95%[3] |
| Protein binding | 97%[3] |
| Metabolism | Liver (mainly CYP3A4-mediated)[3] |
| Elimination half-life | 2.8-3 hours[3] |
| Excretion | Urine (74%), faeces (22%)[3] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C17H18N6 |
| Molar mass | 306.373 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Ruxolitinib, sold under the brand names Jakafi and Jakavi, is a medication used to treat myelofibrosis, polycythemia vera (PCV), and graft-versus-host disease (GvHD).[1] It is used in PCV when hydroxyurea is not sufficient and in GvHD that is unresponsive to other measures.[1] It is taken by mouth.[1]
Common side effects include low platelets, low red blood cells, low neutrophils, bleeding, liver problems, and abnormal lipids.[4] Other side effects may include infection, skin cancer, blood clots, and heart disease.[1] Use in pregnancy may harm the baby.[5] It is a kinase inhibitor.[1]
Ruxolitinib was approved for medical use in the United States in 2011 and Europe in 2012.[1][4] In the United States it costs about 15,800 USD per month as of 2021.[6] In the United Kingdom this amount costs the NHS about £3,000.[5]
References[edit]
- ^ a b c d e f g h i j k "Jakafi- ruxolitinib tablet". DailyMed. 26 February 2020. Archived from the original on 3 November 2020. Retrieved 16 November 2020.
- ^ "Jakavi EPAR". European Medicines Agency (EMA). Archived from the original on 12 November 2020. Retrieved 16 November 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c d e "Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 12 December 2018. Retrieved 16 February 2014.
- ^ a b c "Jakavi". Archived from the original on 12 November 2020. Retrieved 19 October 2021.
- ^ a b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1056. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ "Jakafi Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 October 2021. Retrieved 19 October 2021.